Balance Sheet

Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Aptevo Therapeutics (APVO) Divestments (2017 - 2020)

Aptevo Therapeutics (APVO) has disclosed Divestments for 3 consecutive years, with $28.1 million as the latest value for Q1 2020.

Quarterly Divestments changed N/A to $28.1 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $28.1 million through Dec 2020, up 15182.61% year-over-year, with the annual reading at $28.1 million for FY2020, 561.65% up from the prior year.
Divestments hit $28.1 million in Q1 2020 for Aptevo Therapeutics, up from $65000.0 in the prior quarter.
In the past five years, Divestments ranged from a high of $28.1 million in Q1 2020 to a low of -$714000.0 in Q4 2017.
Historically, Divestments has averaged $5.5 million across 3 years, with a median of $65000.0 in 2018.